RPRX Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 35.07% compared to Royalty Pharma PLC's net margin of -76.18%. Royalty Pharma PLC's return on equity of 8.54% beat Arvinas's return on equity of -32.96%.

Royalty Pharma PLC has a consensus price target of $40.04, signalling upside risk potential of 23.37%. On the other hand Arvinas has an analysts' consensus of $36.39 which suggests that it could grow by 380.07%. Given that Arvinas has higher upside potential than Royalty Pharma PLC, analysts believe Arvinas is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arvinas has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.541%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.62%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $593.6M, which are larger than Arvinas quarterly revenues of $59.2M. Royalty Pharma PLC's net income of $208.2M is higher than Arvinas's net income of -$45.1M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 18.00x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 8.52x versus 2.07x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Biogen has a net margin of 35.07% compared to Royalty Pharma PLC's net margin of 10.87%. Royalty Pharma PLC's return on equity of 8.54% beat Biogen's return on equity of 10.33%.

Royalty Pharma PLC has a consensus price target of $40.04, signalling upside risk potential of 23.37%. On the other hand Biogen has an analysts' consensus of $194.88 which suggests that it could grow by 66.59%. Given that Biogen has higher upside potential than Royalty Pharma PLC, analysts believe Biogen is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.62%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $593.6M, which are smaller than Biogen quarterly revenues of $2.5B. Royalty Pharma PLC's net income of $208.2M is lower than Biogen's net income of $266.7M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 18.00x while Biogen's PE ratio is 10.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 8.52x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of 35.07% compared to Royalty Pharma PLC's net margin of -2.37%. Royalty Pharma PLC's return on equity of 8.54% beat Humana's return on equity of 7.25%.

Royalty Pharma PLC has a consensus price target of $40.04, signalling upside risk potential of 23.37%. On the other hand Humana has an analysts' consensus of $305.65 which suggests that it could grow by 6.58%. Given that Royalty Pharma PLC has higher upside potential than Humana, analysts believe Royalty Pharma PLC is more attractive than Humana.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Humana has a beta of 0.624, suggesting its less volatile than the S&P 500 by 37.637%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.62%. Humana offers a yield of 1.23% to investors and pays a quarterly dividend of $0.89 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $593.6M, which are smaller than Humana quarterly revenues of $29.2B. Royalty Pharma PLC's net income of $208.2M is higher than Humana's net income of -$693M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 18.00x while Humana's PE ratio is 28.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 8.52x versus 0.29x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 35.07% compared to Royalty Pharma PLC's net margin of -46.06%. Royalty Pharma PLC's return on equity of 8.54% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Royalty Pharma PLC has a consensus price target of $40.04, signalling upside risk potential of 23.37%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.43 which suggests that it could grow by 102.34%. Given that Ionis Pharmaceuticals has higher upside potential than Royalty Pharma PLC, analysts believe Ionis Pharmaceuticals is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.35%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.62%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $593.6M, which are larger than Ionis Pharmaceuticals quarterly revenues of $226.6M. Royalty Pharma PLC's net income of $208.2M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 18.00x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 8.52x versus 6.02x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.